In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition~~,~~ comprising 0.5 ng to 20 µg desmopressin and a pharmaceutically acceptable carrier~~, wherein said pharmaceutical composition establishes~~ in a dosage form adapted for intranasal, transmucosal, transdermal, conjunctival, or intradermal administration sufficient to establish in a patient a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picograms desmopressin per mL plasma/serum and to decrease urine production.

2. (Canceled).

3. (Amended) The pharmaceutical composition of claim 1 ~~, wherein said pharmaceutical composition comprises~~ comprising from about 0.05 µg to about 10 µg desmopressin.

4. (Amended) The pharmaceutical composition of claim 1 ~~, wherein said pharmaceutical composition comprises~~ comprising from about 0.1 µg to about 2 µg desmopressin.

5. (Canceled).

6. (Amended) The pharmaceutical composition of claim 1 ~~, wherein said pharmaceutical composition is~~ in ~~the~~ a dosage form of an orodispersible solid adapted for sublingual or buccal administration.

7. (Original) The pharmaceutical composition of claim 1, further comprising an open matrix network, said open matrix network comprising a water-soluble or water-dispersible carrier material that is inert towards desmopressin.

8. (Canceled).

9. (Currently amended) The pharmaceutical composition of claim 1 ~~, wherein said steady plasma/serum desmopressin concentration is in the range~~ in a dosage form sufficient to establish in a patient a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum.

10. - 26. (Canceled).

27. (New) A pharmaceutical dosage form comprising desmopressin and a pharmaceutically acceptable carrier adapted for intranasal, transmucosal, transdermal, conjunctival, or intradermal administration which when administered to a patient establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picograms desmopressin per mL plasma/serum and decreases urine production.

28. (New) The composition of claim 27 which establishes a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum.